CA Patent

CA2894170A1 — Lfa-1 inhibitor formulations

Assigned to Bausch and Lomb Ireland Ltd · Expires 2014-06-26 · 12y expired

What this patent protects

The present invention provides formulations, methods and kits for the treatment of dry eye diseases. In particular, stabilized pharmaceutical compositions comprising the compound of Formula 1 are described herein for a variety of uses including the treatment of dry eye syndrome. …

USPTO Abstract

The present invention provides formulations, methods and kits for the treatment of dry eye diseases. In particular, stabilized pharmaceutical compositions comprising the compound of Formula 1 are described herein for a variety of uses including the treatment of dry eye syndrome. In one aspect, methods and ingredients for improving the stability of compositions of the compound of Formula 1 are described.

Drugs covered by this patent

Patent Metadata

Patent number
CA2894170A1
Jurisdiction
CA
Classification
—
Expires
2014-06-26
Drug substance claim
No
Drug product claim
No
Assignee
Bausch and Lomb Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.